INTRODUCTION
Evidence-based medicine refers to the accurate use of the current best-reported standards in health care [1, 2] . Similarly, guidelines are meant to provide clear recommendations on what surgeons should do. The methodology for developing clinical guidelines must be transparent and should follow a set of predefined rules [3] . Also, the guidelines should suggest the most appropriate action for a typical patient [4] . The recommendations about a comparator could be either for (when the desirable consequences outweigh the undesirable consequences) or against (when the opposite is true) a particular strategy [5] . The Grading of Recommendations Assessment, Development and Evaluation (GRADE) developed a standardized approach to grading the value of evidence and the strength of recommendations. With the GRADE approach, the outcomes were classified as critical and essential or not critical and, if confirmed in the revision of results, are presented in the evidence profiles [5] . As a consequence, many international societies have used them as the standard in guidelines development (Fig. 1) .
THE CLINICAL QUESTION IN THE PICO FORMAT
The first crucial step is to formulate a well-focused question because of the identification of the appropriate resources, and the search for relevant evidence can be time-consuming. The GRADE approach formulates the appropriate clinical questions in that recommendations could answer and asks guideline designers the definition of the importance of each outcome to generate a classification of the recommendation [3] . Guidelines should include recommendations about the most appropriate treatment and should answer clinical management questions, but not about prognosis or aetiology. A question should have 4 components: Patient/Population, Intervention (diagnostic or therapeutic), alternative intervention (Comparison) and the Outcomes of interest (PICO). The potential problems of questions could be the failures of the evaluation of all relevant alternatives (e.g. in international guidelines where treatment options vary in different countries). Two other closely related mistakes are the exclusion of relevant outcomes and the excessive emphasis on surrogate outcomes with questionable importance [3] . The PICO frame facilitates the searching process by identifying the fundamental concepts for an effective search strategy [6] [7] [8] . Even if PICO frames were initially developed to address therapeutic issues, this approach was later extended to all clinical questions [9, 10] ( Table 1) .
The magnitudes of effect of the outcomes in relative terms (e.g. relative risk, hazard ratio, odds ratio) are presented in most original studies and systematic reviews. Nevertheless, the difference between the desirable and undesirable consequences of a recommendation requires the knowledge of the effects on a specific population. The merit of the PICO frame is its transparency about the rationale behind the choice. The balance of desirable and undesirable outcomes determines the direction and influences the strength of a recommendation. This balance depends on the magnitude of the expected desirable and undesirable effects and how patients value specific outcomes [11] .
Although it is worthwhile to specify critical and essential outcomes before beginning the review of the evidence, this review may influence judgements about the importance of the outcomes. In 2 situations, the results of the evidence review may modify the selection of relevant outcomes or their relative importance. A potential benefit of an outcome, initially judged critically, could be no longer critical on a review of the results and, given other established benefits, the intervention could be judged feasible in the absence of a demonstrated benefit on the outcome. For example, in screening for lung cancer, the guideline panel is likely to consider the intervention's impact on all-cause mortality as critical. However, the evidence summary establishes an essential reduction in cause-specific mortality from lung cancer but fails to establish a reduction in all-cause mortality definitively. Therefore, the reduction in cause-specific mortality may be judged sufficiently compelling, even in the absence of a demonstrated reduction in all-cause mortality. All-cause mortality then becomes less relevant and ceases to be a critical outcome [6] . On the other hand, any new intervention could be associated with adverse effects that were not initially present. Significant unexpected toxicity could emerge in approved drugs, and the undiscovered toxicity should be considered as a necessary adverse consequence of any new drug. Therefore, the toxicity becomes critical only when sufficient evidence of its existence emerges [6] .
ASSESSING THE QUALITY OF STUDIES
After the PICO search, GRADE makes a preliminary classification of outcomes and ensures that guidelines address the questions and the quality of the evidence in a systematic manner [6, 11] . Developers of guidelines consider features in controlled trials, such as randomization, allocation concealment and blinding. Intention-to-treat analysis can be used to generate a rating. In observational studies, the appropriate measurement of the exposure and the proper control of confounders should be evaluated. In both controlled and observational trials, developers should take into account the loss to follow-up as well as other aspects of design, conduct and analysis of the investigation that may influence the risk of bias [7] .
Each of the approaches is meant for using available data to verify the likelihood of a publication bias. Prospective registration of all randomized clinical trials enables the authors of reviews to assess when the relevant trials have been conducted because it is possible to ask the responsible investigators to provide the relevant study data. Mandatory registration of clinical trials represents one of the reliable methods of avoiding a publication bias. Consequently, searching of clinical trial registers should be considered when assessing the risk of publication bias [8] . The final categorization of evidence based on the GRADE score does not necessarily relate to the overall methodological quality of any individual randomized controlled trial or review. Somewhat, it relates to the quality of evidence on a specific outcome in our designated population of interest.
In the literature, quality commonly refers to a judgement on the internal validity of an individual study. Although other meanings were attributed to the word 'quality' (typically risk of bias), this meaning should correspond more closely to the standard and non-technical understanding of quality [11] . GRADE judgements refer not to individual studies but to a body of evidence. A body of evidence (e.g. some well-designed and executed trials) may be associated with a low risk of bias, but confidence in effect estimates may be compromised by some other factors (imprecision, inconsistency, indirectness and publication bias). There are also factors, particularly relevant to observational studies, which could rate up quality, including the magnitude of treatment effect and the presence of a dose-response gradient. Well-conducted studies may be part of a body of evidence rated low quality because they only provide indirect or imprecise evidence for the question of interest [11] ( Table 2) . Classifying in the GRADE approach each of the outcomes of interest as critical, substantial but not critical, or not relevant, for making recommendations, experts, clinicians and patients differ in the value of particular outcomes. For example, the outcomes such as mortality or quality of life might be considered critical symptoms as judged by a physician, or valuable but not critical, or not relevant, but perhaps informative, for making a recommendation [3] . In the GRADE system, the study design remains critical, and the unique factor, in judging the quality of evidence. Therefore, in the GRADE system, a body of evidence obtained from randomized trials is initially rated as high quality and that obtained from observational studies as low quality. A well-designed and executed randomized trial or observational study provides a different quality evidence from the one that was poorly conducted. Therefore, relying on the study design alone has apparent limitations. GRADE provides additional quality criteria that serve to overcome this shortcoming. Therefore, 5 factors can reduce the quality of evidence for each study design, and 3 can increase it.
Risk of bias (limitations in study design and/or execution)
Quality decreases when studies suffer from significant methodological limitations that can bias their estimates of the treatment effect as the lack of allocation concealment, lack of blinding (outcomes subjective and assessment highly susceptible to bias), lack of accounting for a significant proportion of patients who started the study (considerable loss to follow-up or the outcome not measured in a significant proportion of patients), failure to adhere to the intention-to-treat principle during the analysis, stopping early for benefit, or selectively reporting outcomes that show an apparent treatment effect and failing to report other outcomes that show no evident effect.
Inconsistency of results
The quality of evidence decreases if widely differing estimates of the treatment effect across individual studies (variability or heterogeneity of results) suggest exact differences in underlying treatment effects. Variability in individual study results may arise from clinical differences in populations, interventions and outcome measures or from methodological limitations (problems with randomization or early termination of trials).
Indirectness of evidence
GRADE distinguishes 2 types of indirectness. Indirect comparison arises when the recommendation addresses the choice between 2 active drugs, but the available studies compared the drugs versus a placebo. An indirect comparison provides lower quality evidence than a head-to-head comparison and is ordinary when choosing between the same class drugs. Evidence supporting the recommendation is also indirect when it comes from studies in which population, intervention, alternative intervention or outcomes of interest were different from those that the recommendation refers to.
Imprecision of results
Estimates of the effect usually have wide confidence intervals that include both essential benefits or no essential effects (or even significant harm) when studies include relatively few patients and few events occur. With the resulting uncertainty in effect, the indeterminate results could lower the quality of the evidence.
Publication bias
The quality of evidence will be decreased if researchers fail to report studies where no effects are presented. Regrettably, one must often speculate about the likelihood of bias. The risk of bias is higher if only a few small studies are available. However, only small trials reported clinically and statistically significant benefits of active treatment, while larger trials showed a much smaller and a statistically not significant effect. Therefore, smaller studies demonstrating smaller effects might not have been published. On rare occasions, the GRADE system offers 3 criteria that could increase the quality of evidence. 
Large magnitude of effect
When based on modelling studies that provide estimates of the magnitude of effect not explained by a bias, the GRADE system defines a relative risk < _0.5 or >2 as the significant effect and a relative risk < _0.2 or >5 as the substantial effect.
Reduction or increase of the demonstrated effect by plausible confounding
All plausible biases may underestimate the exact treatment effect, considering the evidence from these observational studies higher than low quality. A parallel situation exists when observational studies do not demonstrate an association, but all plausible biases increased an intervention effect and raised apparent harmful effects.
Dose-response gradient
A dose-response gradient may also increase the quality of evidence. Moreover, the higher the exposure, the higher the risk [3] .
THE GRADE OF THE EVIDENCE
Needless to say, a systematic review is an essential element to guideline development because it allows the evaluation of the existing evidence and its quality. Systematic reviews and metaanalyses evaluate the evidence systematically and reproducibly, thereby reducing selection bias. The meta-analyses increase the precision of the estimated effects, explore inconsistencies across studies and, finally, provide inferences applicable to a broader range of patients. Meta-analyses could also describe the quality of evidence, including measures of precision. It should be noted that randomized clinical trials and well-conducted observational studies are not always available to guide every clinical question in thoracic surgery. Therefore, a meta-analysis of comparative studies could be associated with lower quality evidence. When direct comparative evidence is not available to guide recommendations, panel members should provide guidance using clinical experience supported by the best interpretation of the available low-quality evidence. Busy practising surgeons will likely appreciate a consensus statement that results from an exhaustive literature search. Nevertheless, surgeons could deviate from recommendations when a patient's clinical context cannot be attributed to a standard scenario [1] .
In particular, GRADE offers a system for rating the strength of the recommendations. The system was finally designed for reviews and guidelines that assess alternative management strategies or interventions, which may also include no intervention or current best management. Nevertheless, GRADE is more than a rating system offering a transparent and structured process for carrying out the steps involved in developing recommendations. GRADE specifies an approach to edging questions, choosing outcomes of interest and rating their importance, and evaluating and incorporating the evidence with considerations of values and preferences of patients to reach specific recommendations [12] . The GRADE system defines 4 grades of evidence: high, moderate, low and very low quality. Table 3 presents what GRADE means for each of these 4 categories.
The quality of evidence is a temporal or space continuum, and any categorization involves unpredictability. Therefore, the oversimplification, the clarity, the transparency and the intuitive understanding of these 4 categories outweigh these limitations [3] . On the other hand, expert opinion is not a type of quality of evidence but an interpretation of existing evidence. Therefore, expert advice is nearly always necessary to integrate and contextualize evidence from either a clinical or a methodological viewpoint. For example, a well-designed and executed randomized trial could provide contradictory quality evidence compared to a poorly conducted clinical trial. Table 4 summarizes the GRADE approach to rating the quality of evidence, which begins with the study design (trials or observational studies) and then addresses 5 reasons to possibly rate down the quality of evidence and 3 reasons to rate up the quality. GRADE provides additional quality criteria likewise that can reduce or increase the quality of evidence for each study evaluated. Methodological limitations, such as the presence of a significant proportion of patients lost to follow-up, lack of blinding in a randomized trial or various additional biases, are responsible for the reduction of the evidence quality [1, 13, 14] . To be able to understand the evidence, and mainly to be able to apply it, a degree of simplification is unavoidable, but it is wise to remember the words of Albert Einstein who said 'Everything should be made as simple as possible, but not simpler'. In situations in which differing criteria would lead to different recommendations, the rating down of clinical evidence should be related to the threshold of the clinical question (Table 5 ) [13] .
FROM THE EVIDENCE TO RECOMMENDATIONS
Each recommendation is based on the evidence deriving from the outcomes of clinical questions. When the quality of evidence differs across the outcomes, GRADE establishes that the lowest grade of quality of evidence determines the overall quality of evidence. Consequently, the overall quality of evidence would be moderate [3] . When using GRADE recommendations, surgeons need to understand the strength of the recommendation and the rating of the certainty of the evidence. Also, crucial additional information, such as remarks, full effects of treatment alternatives, or considerations regarding values and preferences and cost, should be readily accessible. Recommendations developed with the GRADE approach are classified as strong or weak. A 'strong recommendation' reflects the panel's confidence that a desirable consequence of the proposed action outweighs or not the undesirable effects [15] . The outweighing of the desirable effects of an intervention on undesirable effects reflects the strength of a recommendation. Strong recommendations mean that most informed patients would choose the recommended management and that clinicians can structure their interactions with patients accordingly [16] . The usual phrasing for strong recommendations is 'we recommend' or 'surgeons should'. A 'weak' recommendation reflects either a close balance between benefits and downsides, uncertainty regarding the magnitude of advantages and downsides, change or high variability in values and preferences of patients, or not a justification of the cost of the planned intervention [15] . Weak recommendations mean that choices of patients will vary according to their values and preferences, and clinicians must ensure that patient care is in keeping with their values and preferences [16] . A weak recommendation is usually phrased as 'we suggest' or 'it might be considered' (Table 6) . Such information could be typically found in the summary-of-findings tables, which provide the rate for all the relevant outcomes and the numerical values for the relative and absolute estimates of the effect [15] . GRADE is a comprehensive, objective and robust system that displays sufficient reproducibility to be used in everyday practice even by panels with relatively limited exposure to the research methodology [17] . Nevertheless, GRADE has been developed to address questions about alternative management strategies, interventions or policies; it has not been prepared for questions about risk or prognosis. Preparing a guideline entails several steps the GRADE system applies. By overwhelming consensus, GRADE has proved its merit in the evaluation of therapeutic interventions and in addressing clinical rather than public health questions, even if it does not eliminate the need for further reviews (Table 7) . The strength of a recommendation is determined by the balance between desirable and undesirable consequences of alternative management strategies, quality of evidence, variability in values and preferences, and resource use [16] . It is recommended that specialists should consider the type of evidence that they will be evaluating and also the research experience of the appraisers before selecting a critical appraisal and grading system. If the literature to be reviewed encompasses a broader mix of methodologies, including qualitative, sociological or opinion-based evidence as well as quantitative research, it is recommended that all appraisers should have training in appraising and grading evidence using the system to be employed for the guideline (Table 8 ) [18] . Other methodologies were developed in the past to write evidence-based clinical guidelines. The Scottish Intercollegiate Guidelines Network (SIGN) approach was mainly designed for questions of effectiveness [19] . The SIGN method assesses evidence quality based on the type of study in which it was published and emphasizes trial design and not trial quality. SIGN rates quality according to the study design with little consideration of the outcomes or publication bias. For example, using the SIGN classification method, even the most poorly conducted randomized controlled trials can at worst be classified as useful, and any recommendations that arise from this evidence will be graded as strong. Although SIGN is subjective, the classifications system dictates that all the recommendations from randomized controlled trials or meta-analysis of randomized controlled trials will receive a high-quality grading (even if there is a high risk of bias), which makes the system reasonably reproducible. On the contrary, the GRADE methodology considers additional aspects when making recommendations, but they do not form part of the quality of evidence judgement. Conversely, GRADE focuses less on study type and considers multiple aspects of the available data when assessing quality. Nevertheless, the GRADE system is time-consuming because users must consider multiple aspects during their quality assessment, each of which is open to some degree of subjectivity. Hence, a criticism that could be admissibly reported to the GRADE system is that it appears to have been developed by academics for academics. If the increased complexity of GRADE compared with other methods results in the failure of the clinical guideline developers to understand the process, then this will limit GRADE from achieving the objective of being standardized. One potential solution is to produce alternative methods of data display to make the guidelines more user-friendly for surgeons, who are ultimately the end users. Surgeons may find the guidelines less confusing and more straightforward to assimilate if only the outcome of the quality assessment was presented, having understood that this recommendation was defined after a rigorous assessment, using the GRADE approach [20] . The more significant the difference between the desirable and undesirable effects, the higher the likelihood warrant firm recommendation The narrower the gradient, the higher the likelihood warrant a conditional/weak recommendation Quality of evidence
The higher the quality of evidence, the higher the likelihood warrant a substantial recommendation Values and preferences
The more values and preferences vary, or the higher the uncertainty in values and preferences, the higher the likelihood warrant conditional/weak recommendation Costs (resource allocation)
The higher the costs of intervention (higher the resources consumed), the lower the likelihood warrant a substantial recommendation 
